… received single doses of apixaban 5 mg intravenously on day 1 and 10 mg orally on day 3,
… Finally, participants received single doses of apixaban 5 mg intravenously and 10 mg orally …

… Apixaban (Eliquis ® ) is an oral, direct factor Xa inhibitor that is … Like other direct oral
anticoagulants (DOACs), apixaban has … In large phase III trials, oral apixaban was noninferior to …

… Activated factor X (FXa) inhibition has emerged as a … and efficacy data for three factor Xa
inhibitors being developed - … of three orally active FXa inhibitors – rivaroxaban, apixaban, and …

… a small I², as we expected clinical heterogeneity across studies to exist, due to different oral
factor Xa inhibitors (eg apixaban, rivaroxaban, edoxaban), different conventional thrombin …

… We identified 10 new studies with 2950 participants for this update. In total, we included 21 …
), 17 investigated oral factor Xa inhibitors (eight rivaroxaban, five apixaban and four edoxaban…

… The aim of this study was to test the effect of direct oral factor Xa inhibitors—rivaroxaban
and apixaban—on platelet aggregation in patients with nonvalvular atrial fibrillation. …

… It is possible that with the use of anti-factor Xa assay, direct factor Xa inhibitors can be used
more safely in patients with super-high age, low body weight, and/or low renal function. The …

… Apixaban (Eliquis®) is an oral, direct factor Xa inhibitor that is approved for the acute … is
that it does not require laboratory monitoring, there may be situations such as emergent surgery, …

… role of anti-Xa levels in managing patients with an emergent … of rivaroxaban and apixaban
before emergent procedures or … apixaban and rivaroxaban reversal utilizes factor 8 inhibitor …

… Much effort has focused on the development of agents and strategies to reverse the
anticoagulant effect of factor Xa inhibitors, such as rivaroxaban and apixaban. In May 2018, the FDA …